Cerus Corporation (CERS) Stock Score, Valuation & Financial Research
Cerus Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for CERS
Cerus Corporation currently has a Wall Street Score of 20/100. The stored market price is $2.5. Its financial score is 28/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Cerus Corporation does
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipit
CERS financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $2.5
- Market capitalization:
- $503.8M
- Revenue:
- $221.6M
- Net income:
- $-6.8M
- Free cash flow:
- $8.5M
- Cash:
- $18.0M
- Total debt:
- $76.8M
- EPS:
- -0.04
- Financial score:
- 28/100
- Valuation score:
- 0/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $8.5M, showing positive cash generation.
- The balance sheet shows $18.0M of cash versus $76.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 28/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CERS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.